Patient's peripheral blood smear illustrating marked hypochromic microcytic red cells, numerous target cells, polychromasia, poikilocytosis, and anisocytosis with numerous small teardrop forms, ovalocytes, and schistocytes (red cell fragments).
Additional Diagnostic Tests: Analysis of Hb variants was performed on the patient's blood using high performance liquid chromatography (HPLC) with results as shown in Figure 2 . Hb separation by HPLC (Bio-Rad Variant beta-thal short program) revealed a normal Hb F of 0.3% (reference interval, 0-1.8%), a low Hb A2 of 1.6% (reference interval, 2.3-3.5%), and 2 distinct unknown peaks with very short retention times (<0.6 minutes).
4.
The complete blood count and RBC morphology on a peripheral blood smear can be very similar for both iron deficiency anemia and thalassemia. Various RBC indices routinely provided by electronic RBC cell counters can be helpful for differentiating between these 2 conditions. The MCV tends to be lower in thalassemia compared with iron deficiency, and MCV cutoffs of 72 to 75 fL have been recommended for distinguishing between the 2 disorders. [2] The Hb and RBC count can also be used with the MCV to derive indices to discriminate between iron deficiency and thalassemia. [3, 4] Another index often used is the RDW. A normal RDW is commonly found in thalassemia whereas an elevated RDW is common in iron deficiency. However, the RDW can be elevated in some thalassemias, such as hemoglobin H (Hb H) disease and deltabeta-thalassemia. [5] Serum markers of iron status are helpful in differentiating between various causes of microcytic hypochromic anemias ( Table 2 ). Since this patient takes iron supplements, and has normal values for serum markers reflective of iron status, it is unlikely she is iron deficient. An MCV of 61 also argues against this diagnosis. Moreover, the patient does not have a history of an underlying chronic inflammatory disorder. Basophilic stippling and 2 distinct RBC populations are not seen in the peripheral blood film, arguing against lead poisoning and sideroblastic anemia. Numerous target cells are present, which is consistent with a thalassemia.
5.
Other tests that can be performed include Hb electrophoresis, brilliant cresyl blue staining of peripheral blood films, isoelectric focusing, and Hb fractionation by high-performance liquid chromatography (HPLC). Hemoglobin H migrates rapidly in agarose gel electrophoresis at alkaline pH and appears anodal to Hb A. The distance between Hb H and Hb A is approximately the same as the distance between Hb A2 and Hb A. If standard alkaline gel electrophoresis times are used, Hb H can be missed since it will migrate off the gel. It is important to be aware of this possibility and to use shorter electrophoresis times (20 minutes using the Beckman Paragon system) when one suspects the presence of Hb H. [6] In addition, a faint band of Bart's Hb (gamma4) is often seen an equal distance between Hb H and Hb A. Hemoglobin A2 is often decreased and Hb F can be elevated. When using agarose gel electrophoresis at acid pH, a faint band of Hb H can be detected at the point of application. [6] Isoelectric focusing can also be used to detect Hb H; however, this technique is rarely performed by clinical laboratories and is usually only available from reference laboratories. The amount of Hb H detected by any of these methods varies from 1% to 40% of the total Hb. [7] Brilliant cresyl blue staining of peripheral blood films may also be diagnostically helpful in detecting characteristic Hb H inclusions within RBCs. [8, 9] Denaturation and precipitation of unstable Hb H results in diffuse stippling of the RBCs (Hb H inclusions). Brilliant cresyl blue staining was performed (1% brilliant cresyl blue in isotonic saline) on a fresh EDTA-anticoagulated blood sample from this patient and peripheral blood films were examined at 1-and 4-hour intervals. Although reticulocytes stained positive, no Hb H inclusions were observed (data not shown). It is noteworthy that brilliant cresyl blue staining has been shown to be an excellent screening test for Hb H, with studies reporting sensitivities as high as 100% in detecting Hb H inclusions. [8, 9] However, the performance of the brilliant cresyl blue test can vary widely and has been reported to give false-negative results, depending on the dye manufacturer and dye lot-to-lot variability. [6, 8] Hemoglobin fractionation by HPLC of blood from this patient showed the following percentages for each Hb species (reference intervals): Hb A, 97.4% (95% to 98%); Hb A2, 1.6% (2.3% to 3.5%); Hb F, 0.3% (0.0% to 1.8%) ( Figure 2 ). The reduced Hb A2 (1.6%) suggests alpha-thalassemia or Hb E. Two abnormal peaks with short retention times were noted (arrows in Figure 2 ) and most likely represent Hb H, a tetramer of 4 beta-globin chains. [10] These peaks were not included in the calculation to determine the percentage of each Hb. A peak corresponding to Hb E was not seen.
Most likely diagnosis: Hb H disease (clinically manifested as thalassemia intermedia).

7.
Hemoglobin molecules are made up of 2 pairs of different globin chains. Each polypeptide chain contains a porphyrin derivative called heme, and polypeptide chains without the heme moiety are called globins. In normal adults, Hb A is the major hemoglobin and is composed of 2 identical alpha-globin chains and 2 identical beta-globin chains. Thalassemias are a group of hereditary disorders caused by mutations or deletions in one or more globin genes resulting in decreased or absent globin chain production. Alpha-thalassemia results from diminished alphaglobin chain production and is usually an inherited disorder except in very rare circumstances. [11] The majority of alpha-thalassemias are caused by a deletion of one or more alpha-globin genes; nondeletional (inactivation) mutations are less common. [11] Because there are 4 alpha-globin genes on chromosome 16, there are 5 possible deletional combinations. The severity of the disease is related to the number of affected genes. Deletion of both genes from 1 or both chromosomes is called alpha-thalassemia 1 (the double deletion was identified first), whereas deletion of only 1 gene from 1 or both chromosomes is called alpha-thalassemia 2. Heterozygous and homozygous are used to denote 1 or 2 affected chromosomes, respectively. A single alpha-chain deletion (heterozygous alpha-thalassemia 2), also called alpha-thalassemia trait, is clinically silent and found worldwide. These deletions are very common and are found in 30% of African Americans and more than half the people living in Saudi Arabia, India, Thailand, Papua New Guinea, and Melanesia. [12, 13] Deletion of 2 alpha-globin genes (homozygous alpha-thalassemia 2 and heterozygous alpha-thalassemia 1), also called thalassemia minor, is associated with a mild anemia, microcytic RBCs and erythrocytosis. The double gene deletion on 1 chromosome (heterozygous alpha-thalassemia 1) is common in Southeast Asia and the Mediterranean basin, but is rare among African Americans. Thus, ethnic origin should be considered when screening for thalassemia. Deletion of 3 alpha-globin genes (compound heterozygote alpha-thalassemia 1/alpha-thalassemia 2) results in Hb H disease and is clinically classified as thalassemia intermedia. Hemoglobin H disease exhibits marked phenotypic variability and manifests as a moderate to severe hemolytic disease. The excess beta-globin chains are unstable and form tetramers (Hb H) that precipitate slowly within RBCs (Heinz bodies), causing hemolysis or removal from the circulation by the reticuloendothelial system. [11, 14] Clinical severity of the disease is related to the amount of Hb H in RBCs. Hemoglobin H disease is usually caused by detection of both alpha-globin genes on 1 chromosome and deletion of a single alpha-globin gene on the other chromosome. Less common is a point mutation or small insertion/deletion of 1 of the alpha-globin chains on the other chromosome (nondeletional Hb H disease). Hemoglobin H disease is particularly common in Southeast Asia and southern China and is also found in Middle Eastern and Mediterranean populations. It is estimated that Hb H disease is present in 420,000 people in Thailand. [15] Hemoglobin H disease is rarely seen in African Americans. [14] Deletion of all 4 alpha-globin genes (homozygous alpha-thalassemia 1) results in the complete absence of alpha-globin chain production and is not compatible with life. It is also called Hb Bart's hydrops fetalis. An affected fetus dies in utero or soon after premature birth and has gamma-globin tetramers (Hb Bart's) with very high oxygen binding capacity in RBCs. Homozygous alpha-thalassemia 1 syndrome is the most common cause of hydrops fetalis in Southeast Asian and southern China, however it is rarely observed in other populations. [8, 14] 8. DNA-based genotyping would be needed to confirm the diagnosis of Hb H disease. Southern blot analysis of alpha-globin genes can be performed for diagnosis of the most common deletional mutations. [8] Gap-polymerase chain reaction methods have also been developed for some of the more common Mediterranean and Southeast Asian single-and double-gene mutations. [16] Large deletions encompassing the entire zeta-alpha-globin gene cluster can be difficult to detect, requiring probes distal to the deletional breakpoints. [17] Tests to detect less common non-deletional point mutations are often based on direct nucleotide sequencing of a selectively amplified polymerase chain reaction (PCR) product. Multiplex PCR and reverse dotblot hybridization with multiple probes have been used to simplify detection of numerous point mutations; however, a simple approach for all alpha-thalassemia point mutations has not been developed. [11] Southern blot analysis using 2 DNA probes (1 directed to the alpha-globin gene and the other to the zeta globin gene) revealed this patient had 3 alpha-globin genes deleted. A single alpha-globin gene deletion (-4.2 kb) on 1 chromosome 16 and 2 alpha-globin gene deletions (Southeast Asian type) on the other chromosome were identified. The -4.2 kb deletion is one of the most common single alpha-gene deletions. [18] The Southeast Asian type deletion is 1 of the 3 most common deletions involving both alpha-globin genes; the other 2 (Mediterranean and -20.5 kb) are found in the Mediterranean population. [11, 14, 19] 9. The clinical findings in Hb H disease can be quite variable. Some patients are asymptomatic and have a mild disorder, while others have severe anemia with in vivo hemolysis, hepatosplenomegaly, and require frequent blood transfusions. [11, 14] Infants with Hb H disease can have Hb levels that are near normal in the absence of hepatosplenomegaly. [8] Patients with nondeletional alpha-globin gene mutations typically have a more severe form of the disease than patients with deletional mutations. [11, [20] [21] [22] [23] Wide variations in clinical severity are observed in patients with the same genotype, suggesting that other poorly defined factors contribute to the severity of the disease. [11] Marked variation in Hb levels has been observed, ranging from 7.0 to 11.4 g/dL among 41 female patients with deletional Hb H disease. [24] The age at diagnosis also varies widely, ranging from birth to 74 years. [8] A study of 114 Chinese patients with Hb H disease found that only 24% presented with clinical symptoms such as jaundice, anemia, and gallstones. Most patients were found to have Hb H disease after routine health evaluations related to work or pregnancy, or after presenting with infection. [20] Other presenting features include mild dysmorphic facial features, scleral icterus, splenomegaly, and hepatomegaly. [8, 20] The majority of Hb H patients have a fluctuating anemia throughout life but typically are not transfusion-dependent. [8, 11, 20] On occasion, Hb levels can fall dramatically, requiring transfusions. These episodes tend to surround pregnancy, infection, or the ingestion of oxidative agents or drugs. Iron overload, based on markedly increased serum ferritin, is present in approximately 70% of adults with Hb H disease. [11, 20] Ferritin levels do not appear to be associated with transfusion history and are most likely due to increased iron absorption in the setting of in vivo hemolysis and ineffective erythropoiesis. [20] Imaging studies and liver biopsies have shown that the majority of Hb H patients have iron overload and hepatic fibrosis. [20, 25, 26] Cardiac echocardiography in 25 asymptomatic patients demonstrated a correlation between abnormal left ventricular diastolic dysfunction and serum ferritin levels. Three patients who were not transfusion-dependent developed heart failure from iron overload, [20] and 1 patient developed hemosiderosis and diabetes mellitus. [27] 10. Treatment of Hb H disease is mainly preventive and supportive. Folic acid supplementation is usually recommended, especially during the periconceptional period and beyond. [8, 11] Most patients are asymptomatic despite being moderately anemic. Transfusion therapy may be indicated during severe anemia as a result of infection, fever, hypersplenism, or during pregnancy. Splenectomy may lead to clinical improvement in patients with hypersplenism. [8] Cholecystectomy for symptomatic gallstones may also be beneficial. Because of potential complications from iron overload, patients with Hb H disease should be monitored for tissue damage, and chelation therapy should be initiated when indicated. Although there are no guidelines for starting chelation therapy in Hb H patients not dependent on transfusion therapy, therapeutic intervention may be indicated earlier than in transfusion-dependent patients due to the ferri-hydride form of iron that causes more tissue damage. [11, 20] 11. Prenatal screening is recommended for Hb H disease. The American College of Obstetrics and Gynecology currently advocates screening high-risk couples for the potential of having offspring with thalassemia or sickle cell disease. [28] High-risk groups for Hb H disease include those of Southeast Asian or Mediterranean descent. Some states with a significant proportion of Southeast Asians (eg, California) have implemented universal newborn screening programs to detect Hb H disease. [29] In California, the prevalence of Hb H disease among all newborns is 1 per 15,000. African Americans are not at high risk for Hb H disease since heterozygous alphathalassemia 1 is rare among those of African ancestry. [14] However, it should be noted that in areas where multiracial births are common, offspring of African ancestry have been found to have Hb H disease. [29] Couples at increased risk for beta-or alpha-thalassemia should have an MCV obtained as part of the complete blood count. If the MCV is low and iron deficiency anemia has been excluded, follow-up testing should be performed, such as Hb electrophoresis or fractionation and molecular genetic studies. [28, 30] It is strongly recommended that all individuals with Hb H disease near or at reproductive age have his or her partner screened for alpha-and beta-thalassemia carrier status. [11, 28, 30] If the partner has heterozygous alphathalassemia 2 (a single alpha-globin gene deletion or inactivation), the fetus has a 25% chance of having Hb H disease. If the partner has homozygous alpha-thalassemia 2, the fetus has a 50% risk of having Hb H disease. If the partner has heterozygous alpha-thalassemia 1, the fetus has a 25% chance of having Hb H disease and a 25% chance of having Hb Bart's hydrops fetalis. Lastly, if the partner has Hb H disease, the fetus has a 50% chance of having Hb H disease and a 25% chance of having Hb Bart's hydrops fetalis. Prenatal diagnosis is generally not warranted for fetuses at risk for Hb H disease; [11] however, genetic counseling and prenatal diagnosis should be available for fetuses at risk of Hb Bart's hydrops fetalis. [6, 11, 28, 30] Analysis of fetal DNA may be obtained by chorionic villus sampling or amniocentesis. Ultrasound monitoring may also be offered as an alternative to invasive procedures; however, hydropic changes may not be evident until the second trimester. [11, 28, 30] 
